CytoDyn Announces Executive Leadership Changes and Appointments
Company Announcements

CytoDyn Announces Executive Leadership Changes and Appointments

CytoDyn (CYDY) has released an update to notify the public and investors about its officers.

CytoDyn Inc. appointed Jacob P. Lalezari, M.D. as its Chief Executive Officer effective January 26, 2024, with a $400,000 initial annual base salary, potential bonuses, and stock options but no severance benefits. Separately, Mitchell Cohen was named Interim CFO by the company through an agreement with InterimExecs beginning February 1, 2024, without additional benefits or severance, and can be terminated with a 30-day notice. Antonio Migliarese announced his resignation as CFO effective January 31, 2024, with his last day being February 15, 2024.

For further insights into CYDY corporate activity, check out TipRanks’ Insiders Trading Activity page.

Related Articles
TheFlyCytoDyn appoints Melissa Palmer as lead consultant in hepatology
TheFlyCytoDyn appoints Max Lataillade as head of clinical development
TheFlyCytoDyn engages Syneos Health as CRO for Phase II oncology trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App